BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33712363)

  • 1. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
    Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case-control study.
    Pan CH; Chien SC; Chen CJ; Shih CM; Hsieh MH; Huang CY; Bi WF; Chan CS; Kao YT; Hsiao CY; Chiang SJ; Chiang KH; Huang JH; Liu YR; Luo JD; Huang HY; Wu CH
    BMC Cardiovasc Disord; 2021 Feb; 21(1):77. PubMed ID: 33557763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of high level of hs-CRP with in-stent restenosis: A case-control study.
    Baktashian M; Saffar Soflaei S; Kosari N; Salehi M; Khosravi A; Ahmadinejad M; Moohebati M; Ebrahimi M; Rahmani F; Khameneh-Bagheri R; Ahmadi M; Sadabadi F; Tayefi M; Bazhdanzadeh S; Ferns GA; Hashemi SM; Pasdar A; Ghayour-Mobarhan M
    Cardiovasc Revasc Med; 2019 Jul; 20(7):583-587. PubMed ID: 30232022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
    Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
    Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis.
    He M; Gong Y; Shi J; Pan Z; Zou H; Sun D; Tu X; Tan X; Li J; Li W; Liu B; Xue J; Sheng L; Xiu C; Yang N; Xue H; Ding X; Yu C; Li Y
    PLoS One; 2014; 9(11):e112043. PubMed ID: 25427155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
    He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention.
    Dai R; Liu Y; Zhou Y; Xiong X; Zhou W; Li W; Zhou W; Chen M
    J Clin Lab Anal; 2020 Jan; 34(1):e23013. PubMed ID: 31495986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visit-to-visit HbA
    Yang CD; Shen Y; Lu L; Yang ZK; Hu J; Zhang RY; Shen WF; Ding FH; Wang XQ
    Cardiovasc Diabetol; 2020 Sep; 19(1):133. PubMed ID: 32887588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease.
    Dong J; Liang YZ; Zhang J; Wu LJ; Wang S; Hua Q; Yan YX
    J Atheroscler Thromb; 2017 Apr; 24(4):430-441. PubMed ID: 27629254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of plasma Quaking and cyclooxygenase-2 predict in-stent restenosis in patients with coronary artery disease after percutaneous coronary intervention.
    Wang P; Kuang Y; Liu Y; Zhang Y; Gao H; Ma Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):739-747. PubMed ID: 35837773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography.
    Wan YL; Tsay PK; Chen CC; Juan YH; Huang YC; Chan WH; Wen MS; Hsieh IC
    Int J Cardiovasc Imaging; 2016 Jun; 32 Suppl 1():105-15. PubMed ID: 27106698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.